BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29173153)

  • 1. Therapeutic potential of drug delivery by means of lipid nanoparticles: reality or illusion?
    Uner M; Damgalı S; Ozdemir S; Celik B
    Curr Pharm Des; 2017 Nov; ():. PubMed ID: 29173153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration.
    Fonseca-Santos B; Silva PB; Rigon RB; Sato MR; Chorilli M
    Curr Med Chem; 2020; 27(22):3623-3656. PubMed ID: 31232233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers.
    Shidhaye SS; Vaidya R; Sutar S; Patwardhan A; Kadam VJ
    Curr Drug Deliv; 2008 Oct; 5(4):324-31. PubMed ID: 18855604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanostructured lipid carriers system: recent advances in drug delivery.
    Iqbal MA; Md S; Sahni JK; Baboota S; Dang S; Ali J
    J Drug Target; 2012 Dec; 20(10):813-30. PubMed ID: 22931500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems.
    Uner M
    Pharmazie; 2006 May; 61(5):375-86. PubMed ID: 16724531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review.
    Garcês A; Amaral MH; Sousa Lobo JM; Silva AC
    Eur J Pharm Sci; 2018 Jan; 112():159-167. PubMed ID: 29183800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances and patents on solid lipid nanoparticles.
    Sawant KK; Dodiya SS
    Recent Pat Drug Deliv Formul; 2008; 2(2):120-35. PubMed ID: 19075903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural Lipids as Structural Components of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Topical Delivery.
    Dobreva M; Stefanov S; Andonova V
    Curr Pharm Des; 2020; 26(36):4524-4535. PubMed ID: 32410552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers.
    Thatipamula R; Palem C; Gannu R; Mudragada S; Yamsani M
    Daru; 2011; 19(1):23-32. PubMed ID: 22615636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization Methods for Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC).
    Andonova V; Peneva P
    Curr Pharm Des; 2017 Nov; ():. PubMed ID: 29141534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery.
    Souto EB; Wissing SA; Barbosa CM; Müller RH
    Int J Pharm; 2004 Jun; 278(1):71-7. PubMed ID: 15158950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics.
    Bhaskar K; Krishna Mohan C; Lingam M; Jagan Mohan S; Venkateswarlu V; Madhusudan Rao Y; Bhaskar K; Anbu J; Ravichandran V
    Drug Dev Ind Pharm; 2009 Jan; 35(1):98-113. PubMed ID: 18665979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primaquine Loaded Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), and Nanoemulsion (NE): Effect of Lipid Matrix and Surfactant on Drug Entrapment, in vitro Release, and ex vivo Hemolysis.
    Wu KW; Sweeney C; Dudhipala N; Lakhani P; Chaurasiya ND; Tekwani BL; Majumdar S
    AAPS PharmSciTech; 2021 Sep; 22(7):240. PubMed ID: 34590195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of lipid nanoparticles for transdermal loteprednol etabonate delivery.
    Üner B; Özdemir S; Taş Ç; Özsoy Y; Üner M
    J Microencapsul; 2022 Jun; 39(4):327-340. PubMed ID: 35583383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes.
    Souto EB; Müller RH
    Handb Exp Pharmacol; 2010; (197):115-41. PubMed ID: 20217528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles.
    Martins S; Sarmento B; Ferreira DC; Souto EB
    Int J Nanomedicine; 2007; 2(4):595-607. PubMed ID: 18203427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of oral absorption of oxyresveratrol using lipid based nanoparticles.
    Sangsen Y; Wiwattanawongsa K; Likhitwitayawuid K; Sritularak B; Wiwattanapatapee R
    Colloids Surf B Biointerfaces; 2015 Jul; 131():182-90. PubMed ID: 25988282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid nanocarriers (LNC) and their applications in ocular drug delivery.
    Puglia C; Offerta A; Carbone C; Bonina F; Pignatello R; Puglisi G
    Curr Med Chem; 2015; 22(13):1589-602. PubMed ID: 25666802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications.
    Gokce EH; Korkmaz E; Dellera E; Sandri G; Bonferoni MC; Ozer O
    Int J Nanomedicine; 2012; 7():1841-50. PubMed ID: 22605933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery.
    Pathak P; Nagarsenker M
    AAPS PharmSciTech; 2009; 10(3):985-92. PubMed ID: 19641997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.